doi:10.16150/j.1671-2870.2017.04.020

[1] Chen W, Zheng R, Zeng H, et al.The incidence and mortality of major cancers in China, 2012[J]. Chin J Cancer,2016,35(1):73.
[2] Weiler-Sagie M, Bushelev O, Epelbaum R, et al.(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients[J]. J Nucl Med,2010,51(1):25-30.
[3] Eichenauer DA, Engert A, André M, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2014,25(Suppl 3):iii70-iii75.
[4] Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma(DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2015,26( Suppl 5):v116-v125.
[5] Dreyling M, Ghielmini M, Rule S, et al.Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2016,27(suppl 5):v83-v90.
[6] Cheson BD, Horning SJ, Coiffier B, et al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group[J]. J Clin Oncol,1999,17(4):1244.
[7] Cheson BD, Pfistner B, Juweid ME, et al.Revised response criteria for malignant lymphoma[J]. J Clin Oncol,2007,25(5):579-586.
[8] Meignan M, Gallamini A, Meignan M, et al.Report on the First International Workshop on Interim-PET-Scan in Lymphoma[J]. Leuk Lymphoma,2009,50(8):1257-1260.
[9] Fallanca F, Alongi P, Incerti E, et al.Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC)[J]. Eur J Nucl Med Mol Imaging,2016,43(10):1837-1848.
[10] Cheson BD, Fisher RI, Barrington SF, et al.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol,2014,32(27):3059-3068.
[11] Biggi A, Gallamini A, Chauvie S, et al.International va-lidation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers[J]. J Nucl Med,2013,54(5):683-690.
[12] Barrington SF, Mikhaeel NG, Kostakoglu L, et al.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol,2014,32(27):3048-3058.
[13] Pregno P, Chiappella A, Bellò M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with ritu-ximab-CHOP[J]. Blood,2012 Mar 1,119(9):2066-73.
[14] Dupuis J, Berriolo-Riedinger A, Julian A, et al.Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS[J]. J Clin Oncol,2012,30(35):4317-4322.
[15] Juweid ME, Stroobants S, Hoekstra OS, et al.Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J]. J Clin Oncol,2007,25(5):571-578.
[16] Boellaard R, Delgado-Bolton R, Oyen WJ, et al.FDG PET/CT: EANM procedure guidelines for tumour ima-ging: version 2.0[J]. J Clin Oncol,2007,25(5):571-578.
[17] Itti E, Lin C, Dupuis J, et al.Prognostic value of interim ¹⁸F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy[J]. J Nucl Med,2009,50(4):527-533.
[18] Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma[J]. Blood,2011 Jul 7,118(1):37-43.
[19] Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab[J]. J Clin Oncol, 2012 Jan 10,30(2):184-90.
[20] Nols N, Mounier N, Bouazza S, et al.Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2014,55(4):773-780.
[21] Agostinelli C, Gallamini A, Stracqualursi L, et al.The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study[J]. Lancet Haematol,2016,3(10):e467-e479.
[22] Adams HJ, Nievelstein RA, Kwee TC.Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis[J]. Br J Haematol,2015,170(3):356-366.
[23] Micallef IN, Maurer MJ, Wiseman GA, et al.Epratuzu-mab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma[J]. Blood,2011,118(15):4053-4061.
[24] Adams HJ, Kwee TC.Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis[J]. Crit Rev Oncol Hematol,2016,106:55-63.
[25] Dührsen U, Hüttmann A, Jöckel KH, et al.Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial[J]. Leuk Lymphoma,2009,50(11):1757-1760.
[26] Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. ¹⁸F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review[J]. Haematologica,2006,91(4):522-529.
[27] Cerci JJ, Trindade E, Pracchia LF, et al.Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy[J]. J Clin Oncol,2010,28(8):1415-1421.
[28] Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma[J]. Ann Oncol,2011,22(4):910-915.
[29] Trotman J, Fournier M, Lamy T, et al.Positron emission tomography-computed tomography(PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants[J]. J Clin Oncol,2011,29(23):3194-3200.
[30] Adams HJ, Nievelstein RA, Kwee TC.Outcome of Hodgkin Lymphoma Patients With a Posttreatment ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET)-negative residual mass: systematic review and meta-analysis[J]. Pediatr Hematol Oncol,2015,32(8):515-524.
[31] Dabaja BS, Phan J, Mawlawi O, et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2013 Dec,54(12):2631-2638.
[32] Liedtke M, Hamlin PA, Moskowitz CH, et al.Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population[J]. Ann Oncol,2006,17(6):909-913.
[33] Lamonica D, Graf DA, Munteanu MC, et al.¹⁸F-FDG PET for measurement of response and prediction of outcome to relapsed or refractory mantle cell lymphoma therapy with bendamustine-rituximab[J]. J Nucl Med,2017,58(1):62-68.
[34] Chang Y, Fu X, Sun Z, et al.Utility of baseline, interim and end-of-treatment ¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J]. Sci Rep,2017,7:41057.
[35] Ham JS, Kim SJ, Choi JY, et al.The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma[J]. Blood Cancer J,2016,6:e395.
[36] van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of ¹⁸F-FLT and ¹⁸F-FDG for differentiating tumor from inflammation in a rodent model[J]. J Nucl Med,2004,45(4):695-700.
[37] Minamimoto R, Fayad L, Advani R, et al.Diffuse Large B-Cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring[J]. Radiology,2016,280(1):220-229.
[38] Jauw YW, Zijlstra JM, de Jong D, et al. Performance of 89Zr-Labeled-Rituximab-PET as an imaging biomarker to assess CD20 targeting: A pilot study in patients with relapsed/refractory diffuse large B cell lymphoma[J]. PLoS One,2017,12(1):e0169828.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	FENG Guowei, ZHANG Xiaojuan, GUO Rui, GUAN Zhe, WANG Yue. The prognostic value of pretreatment ¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 533-539.
[2]	YUE Jingjing, SONG Qi, JIANG Xufeng, WANG Li, ZHAO Weili, YAN Fuhua. Comparison of magnetic resonance whole body diffusion weighted imaging with FS-T2WI and FDG-PET/CT for initial staging and detection of lesion in newly diagnosed lymphoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 540-546.
[3]	MENG Leijun, ZHANG Jing, WANG Xueli, LI Zhi, ZHANG Hong, ZENG Naiyan. Identification of differentially expressed target genes in pediatric Burkitt lymphoma and its clinical application [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 248-257.
[4]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 630-633.
[5]	MA Yuanyuan, WANG Yan, SONG Qi, CHENG Kemin, ZHAO Xia, WANG Li, JIANG Xufeng, ZHAO Weili, YAN Fuhua. Analysis of CT imaging characteristics of primary pulmonary lymphoma and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 533-537.
[6]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 512-520.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 557-560.
[8]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 460-463.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(04): 432-433.
[10]	LI Jiaming, ZHANG Sujiang, WANG Ying, YAN Zeying, LIU Zhiyin, SUN Haimin, CHEN Yubao, CHEN Yu, LUO Fangxiu, SUN Jing. Chronic myelomonocytic leukemia accompanied with extranodal lymphoma : a clinical feature analysis [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 76-81.